IVIG Induction May Be Helpful in Highly Sensitized Patients after Heart Transplantation
Cedars Sinai Medical Center, Los Angeles.
Meeting: 2018 American Transplant Congress
Abstract number: B65
Keywords: Antibodies, Drug interaction, Heart/lung transplantation, IVIG
Session Information
Session Name: Poster Session B: Heart and VADs: All Topics
Session Type: Poster Session
Date: Sunday, June 3, 2018
Session Time: 6:00pm-7:00pm
Presentation Time: 6:00pm-7:00pm
Location: Hall 4EF
Purpose: Strategies for sensitized patients undergoing heart transplant include post-op anti-thymocyte globulin (ATG) induction therapy as well as intravenous immunoglobulin (IVIG). We sought to assess whether the combination of IVIG and ATG affects the development of donor-specific antibodies (DSA) post-heart transplant (HTx) and clinical outcomes.
Methods: Between 2010 and 2015, we assessed 585 heart transplant patients. Of these, 43 patients were treated with both ATG induction therapy and IVIG and 215 were treated with ATG alone. Endpoints included 2-year freedom from de novo DSA development, 2-year survival, and 2-year freedom from cardiac allograft vasculopathy as defined by ≥ 30% stenosis by angiography.
Results: The ATG and IVIG group compared to the ATG alone group had a significantly higher pre-transplant mean PRA (72.0% vs 58.3%, p=0.044). Patients given ATG and IVIG had a similar 2-year freedom from de novo DSA development (see table). There was no significant difference in 2-year survival or 2-year freedom from CAV between the groups.
Conclusion: Patients who were treated with both ATG and IVIG compared to ATG induction therapy alone had similar outcomes. However, the addition of IVIG to ATG may have had benefit as this group had significantly higher pre-transplant PRA in which 2-year de novo DSA development and clinical outcomes were similar between study groups. Longer follow-up is needed to confirm these findings.
Endpoints | ATG + IVIG (n=43) | ATG Alone (n=215) | Log-Rank P-Value |
2-Year Freedom fromDe NovoDSA Development | 88.4% | 89.3% | 0.917 |
2-Year Survival | 81.4% | 89.3% | 0.322 |
2-Year Freedom from CAV | 86.0% | 90.2% | 0.643 |
CITATION INFORMATION: Patel J., Kittleson M., Kransdorf E., Levine R., Dimbil S., Geft D., Chang D., Czer L., Kobashigawa J. IVIG Induction May Be Helpful in Highly Sensitized Patients after Heart Transplantation Am J Transplant. 2017;17 (suppl 3).
To cite this abstract in AMA style:
Patel J, Kittleson M, Kransdorf E, Levine R, Dimbil S, Geft D, Chang D, Czer L, Kobashigawa J. IVIG Induction May Be Helpful in Highly Sensitized Patients after Heart Transplantation [abstract]. https://atcmeetingabstracts.com/abstract/ivig-induction-may-be-helpful-in-highly-sensitized-patients-after-heart-transplantation/. Accessed October 11, 2024.« Back to 2018 American Transplant Congress